Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
771 people get ITMN articles and Market Currents by email alert.
Get email alerts on ITMN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 17, 2013)
-
-
PR Newswire (Feb 21, 2013)
-
4 Biotech Stocks On The ClockStock Traders Daily • Tue, Feb 19 -
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 11, 2013)
-
-
-
PR Newswire (Jan 14, 2013)
-
PR Newswire (Jan 2, 2013)
-
InterMune Gearing Up For Another Round With The FDABrian L. Wilson • Thu, Nov 29, 2012
To learn more about Seeking Alpha Pro, click here.
-
-
-
InterMune Gearing Up For Another Round With The FDABrian L. Wilson • Thu, Nov 29, 2012
-
-
-
-
InterMune: European Market May Open Its Doors to This BiotechIan Wyatt • Fri, Jan 14, 2011 -
Hedge Fund Balyasny Ramps Up Intermune PositionMarket Folly • Tue, Jun 29, 2010 -
-
Intermune Drops Right Back Down AgainDerek Lowe • Wed, May 5, 2010 -
InterMune's Surprising RiseDerek Lowe • Thu, Mar 11, 2010
-
-
-
4 Biotech Stocks On The ClockStock Traders Daily • Tue, Feb 19
-
-
-
-
-
-
-
-
7 Liquid Small-Cap Healthcare Stocks Rated Buy Or Better By AnalystsZetaKap • Tue, Aug 28, 2012 -
-
6 Biotech Stocks That Analysts Give The Green LightZetaKap • Fri, Jul 27, 2012
-
-
-
-
-
-
-
-
InterMune's CEO Discusses Q3 2012 Results - Earnings Call TranscriptWed, Nov 7, 2012
-
InterMune's CEO Discusses Q2 2012 Earnings - Earnings Call TranscriptMon, Jul 23, 2012
-
InterMune, Inc. Q3 2009 Earnings Call TranscriptTue, Nov 10, 2009
-
InterMune, Inc. Q2 2009 Earnings Call TranscriptThu, Aug 6, 2009
-
InterMune, Inc. Q1 2009 Earnings Call TranscriptThu, Apr 30, 2009
-
InterMune, Inc., Q4 2008 Earnings Call TranscriptThu, Feb 26, 2009
-
InterMune, Inc. Q3 2008 Earnings Call TranscriptWed, Nov 19, 2008
-
InterMune Inc. Q1 2008 Earnings Call TranscriptMon, May 19, 2008
-
InterMune Inc. Q4 2007 Earnings Call TranscriptSun, Feb 10, 2008
-
PR Newswire (Apr 24, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Feb 21, 2013)
-
PR Newswire (Feb 14, 2013)
-
PR Newswire (Feb 11, 2013)
-
PR Newswire (Jan 14, 2013)
-
PR Newswire (Jan 2, 2013)
-
at MarketWatch.com (Nov 8, 2012)
-
PR Newswire (Nov 7, 2012)
-
PR Newswire (Oct 31, 2012)
-
at MarketWatch.com (Oct 3, 2012)
-
at CNBC.com (Oct 3, 2012)
-
PR Newswire (Oct 2, 2012)
-
PR Newswire (Sep 11, 2012)
-
PR Newswire (Sep 3, 2012)
-
PR Newswire (Aug 27, 2012)
-
at Fox Business (Aug 20, 2012)
ITMN vs. ETF Alternatives
Company Description
We are a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. Hepatology is the field of medicine concerned with the diagnosis and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Thursday, November 8, 2012, 9:10 AM
Premarket gainers: DUSA +38%. MTSL +28%. USAT +15%. WLL +11%. ITMN +11%. SD +9%. QCOM +9%. THQI +8%. EZCH +7%. ALU +6%. MWW +7%. TTM +6%. DF +5%.
Losers: CPRX -56%. BCRX -34%. PANL -25%. SVNT -19%. SGEN -11%. MNST -10%. CNQR -9%. TNK -9%. NBG -8%. PSTI -8%. MAKO -7%. WINI -6%. AUI -5%. Comment! [On the Move] - Wednesday, November 7, 2012, 4:36 PM InterMune (ITMN): Q3 EPS of $0.04 beats by $0.88. Revenue of $14.9M beats by $8.6M. Shares +5.9% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Wednesday, November 7, 2012, 12:10 AM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
- Tuesday, November 6, 2012, 5:35 PM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
- Thursday, November 1, 2012, 12:10 AM Notable earnings after Thursday’s close: AIG, AIV, ALSK, ATML, BKD, BMR, CAR, CENX, CHK, DCT, DDR, DWA, EIX, EQIX, FLR, FSLR, GLUU, HAIN, HIG, HTGC, INT, ITMN, JMBA, JOE, KERX, KOG, LIFE, LLNW, LNC, LNKD, LVS, MDLZ, MELI, MNKD, NEM, NGD, NKTR, NLY, OMPI, ONNN, ONXX, OPEN, PBI, PCLN, ROVI, RSG, SAM, SBUX, SHO, SKUL, SPWR, SWKS, SWN, TRIP, UNTD, VNO, VRTX, WBMD, WIT, WPRT, YELP, ZAGG, ZIOP Comment! [Earnings]
- Wednesday, October 31, 2012, 5:35 PM Notable earnings after Thursday’s close: AIG, AIV, ALSK, ATML, BKD, BMR, CAR, CENX, CHK, DCT, DDR, DWA, EIX, EQIX, FLR, FSLR, GLUU, HAIN, HIG, HTGC, INT, ITMN, JMBA, JOE, KERX, KOG, LIFE, LLNW, LNC, LNKD, LVS, MDLZ, MELI, MNKD, NEM, NGD, NKTR, NLY, OMPI, ONNN, ONXX, OPEN, PBI, PCLN, ROVI, RSG, SAM, SBUX, SHO, SKUL, SPWR, SWKS, SWN, TRIP, UNTD, VNO, VRTX, WBMD, WIT, WPRT, YELP, ZAGG, ZIOP Comment! [Earnings]
- Tuesday, October 2, 2012, 6:52 PM InterMune (ITMN) +5.7% AH after announcing Canada's national health service has approved its Esbriet pulmonary fibrosis drug - the company expects sales to begin on Jan. 1. Esbriet has already been approved for use in Japan, South Korea, and 29 European countries, but FDA approval is still pending the outcome of clinical trials. (previous) Comment! [Healthcare, On the Move]
- Tuesday, August 28, 2012, 4:10 PM Hyperion Therapeutics (HPTX -1.2%) names Daniel G. Welch to its Board of Directors. Mr. Welch currently serves as Chairman, CEO and President of InterMune (ITMN +1%). Mr. Welch brings more than 30 years of experience in the biotechnology and pharmaceutical industries. 1 Comment [Healthcare]
- Monday, July 23, 2012, 7:43 AM InterMune (ITMN): Q2 EPS of $0.10 misses by $0.09. Revenue of $5.54M (+13% Y/Y). (PR) Comment! [Earnings, Healthcare]
- Thursday, May 24, 2012, 10:52 AM InterMune (ITMN -1.4%) sells its Actimmune interferon gamma-1b business to privately held Vidara Therapeutics International for $55M in cash plus a two-year royalty stream. The company had stopped active development for Actimmune several years ago, preferring to focus its efforts on other R&D operations such as its Pirfenidone treatment for idiopathic pulmonary fibrosis. Comment! [Healthcare, On the Move]
- Friday, April 27, 2012, 12:50 PM Shares of InterMune (ITMN -14.5%) take a hit after posting a wider Q1 loss and missing on revenue estimates. Top line Esbriet sales came in short of reduced expectations, with just $4.9M in net sales. Comment! [Healthcare, On the Move, Earnings]
- Thursday, April 26, 2012, 5:56 PM InterMune (ITMN): Q1 EPS of -$0.74 misses by $0.04. Revenue of $8.9M (+39.1% Y/Y) misses by $1.7M. Shares -2.2% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Tuesday, April 10, 2012, 11:26 AM Brean Murray is cutting its price target to $37 from $42 on InterMune (ITMN -1%) to reflect a more conservative outlook than the guidance management provided. The firm cites the potential denial of European coverage for Esbriet and a subsequent delay in the commercialization. Comment! [Healthcare]
- Monday, April 9, 2012, 3:03 PM InterMune (ITMN -16.4%) tumbles on news that a key clinical trial for its respiratory drug Esbriet has been delayed. Last week, ITMN said it didn't expect enrollment for the Phase 3 clinical trial to be completed until the end of 2012; it had previously forecast enrollment would be completed in Q2. Citing the delay, Jefferies and Leerink Swann cut price targets on the shares. Comment! [Healthcare, On the Move]
- Thursday, April 5, 2012, 1:03 PM InterMune (ITMN +6.1%) rallies after Wells Fargo notes French regulators gave a favorable rating to the company's Esbriet lung disease drug. Wells believes the rating should allow InterMune to "negotiate premium pricing" for Esbriet. (previously) Comment! [Healthcare, On the Move, Quick Ideas]
- Thursday, March 15, 2012, 11:16 AM Shares of InterMune (ITMN +8.8%) run higher after the company announces that its lung disease drug Esbriet gained approval with a Germany review committee. The action clears a path for the treatment to be approved by the nation's health insurers and helps increase confidence that France will also allow the therapy. Comment! [On the Move, Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Hedgephone
ITMN, chasers a chasin.... gotta love the hot dot! in ITMN the "hot" play on Europe's recommendation to look at a trial - 110K is entire mkt - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES